KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC

Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: 1198-1200

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2021.06.014

Authors with CRIS profile

Involved external institutions

Philipps-Universität Marburg Germany (DE) Duke-NUS Medical School / 杜克—国大医学研究生院 Singapore (SG) Baylor University (BU) United States (USA) (US) Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) United States (USA) (US) Queen Mary, University of London United Kingdom (GB) University of Sydney (USYD) Australia (AU) Klinikum der Universität München Germany (DE) HELIOS Kliniken Germany (DE) Sungkyunkwan University (SKKU) Korea, Republic of (KR) Yale University United States (USA) (US) Champalimaud Foundation / Fundação Champalimaud Portugal (PT) Quirónsalud Spain (ES) Kliniken Essen-Mitte Germany (DE) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE) Cedars-Sinai Medical Center United States (USA) (US) Hokkaido Cancer Society Japan (JP)

How to cite

APA:

Schmid, P., Cortes, J., Dent, R., Pusztai, L., Mcarthur, H., Kummel, S.,... O'Shaughnessy, J. (2021). KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC. In ANNALS OF ONCOLOGY (pp. 1198-1200). AMSTERDAM: ELSEVIER.

MLA:

Schmid, P., et al. "KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. 1198-1200.

BibTeX: Download